A topical acetyl octapeptide studied in cosmetic science as a SNAP-25–related expression-line research ingredient.
Pre-loaded with a typical SNAP-8 vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for SNAP-8. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 3 mcg – 10 mcg | twice daily topical | topical | Cosmetic solution use levels in finished formulas (manufacturer-linked clinical cosmetology) Values here are percent of commercial SNAP-8 solution in a cream/serum (commonly 3–10%), not mcg injectable peptide. The bulk solution itself is a dilute peptide preparation. |
| 1 mcg – 100 mcg | per patch protocol | topical / microneedle-assisted dermal delivery | Microneedle patch clinical cosmetology studies including acetyl octapeptide-3 Published patch studies evaluate safety/efficacy of peptide-loaded systems; exact peptide micrograms are formulation-specific. |
People searching this page also look for: snap-8 peptide injection dosage chart, snap-8 peptide injection dosage, snap-8 peptide injection dosage chart pdf, snap 8 peptide dosage, snap 8 peptide injection dosage, snap 8 peptide injection dosage before and after, snap-8 peptide dosage, snap 8 peptide injection dosage chart pdf.
SNAP-8 (acetyl octapeptide-3) is an eight-amino-acid cosmetic peptide elongated from the acetyl hexapeptide-8 (Argireline) scaffold. It is investigated as a topical modulator of SNARE-complex machinery involved in catecholamine release at neuromuscular junctions of facial expression muscles.
Evidence is strongest in cosmetic-ingredient and delivery-system literature rather than large independent drug trials. Manufacturer-linked clinical cosmetology work and later microneedle-patch studies examine wrinkle-depth and skin-quality endpoints after repeated topical application of dilute peptide solutions.
SNAP-8 is not an injectable research peptide in the GH-secretagogue sense. Dosage education should emphasize percent strength of cosmetic solutions and topical frequency, not subcutaneous mcg charts.
SNAP-8 is designed to interfere with SNAP-25 participation in SNARE complex assembly, reducing vesicle-fusion efficiency for acetylcholine release in a milder, topical paradigm compared with botulinum toxin cleavage of SNAP-25. Less neurotransmitter release at expression-muscle junctions is the proposed path to softer dynamic lines. As a topical oligopeptide, penetration and vehicle design strongly influence observed activity.
cosmetic peptide formulation · expression-line / wrinkle cosmetology · SNARE complex modulation · microneedle and patch delivery systems · comparative studies vs acetyl hexapeptide-8
Cosmetic chemists, dermatocosmetic clinical units, and transdermal delivery engineers are the main research users. Injectables-focused peptide labs sometimes analyze it only as a comparator or analytical target in multi-peptide skincare products.
Finished SNAP-8 solutions and serums are typically stored cool and away from light; avoid high-heat compounding steps after peptide addition. Lyophilized raw peptide, when used by formulators, is kept dry and cold until incorporated into a validated vehicle.
Cosmetic research frequently combines SNAP-8 with acetyl hexapeptide-8, moisturizing polymers, antioxidants, or hyaluronic acid delivery systems. The goal is complementary barrier, hydration, and expression-line pathways in a topical chassis. This is formulation stacking, not an injectable peptide stack.
The questions people actually search for, answered plainly.
Cosmetic research and supplier guidance commonly use about 3–10% of a commercial SNAP-8 peptide solution in the final topical formula, applied once or twice daily in study designs. That is a formulation percentage, not a subcutaneous mcg dose.
If starting from lyophilized raw peptide, formulators use validated aqueous vehicles, not necessarily bacteriostatic water meant for multi-dose injections. Many users never recon a vial at all because they buy a pre-made cosmetic solution.
Topical studies often apply the finished product twice daily to expression-line areas. There is no standard daily injectable schedule in legitimate SNAP-8 literature.
Useful charts list percent solution in emulsion/serum, application frequency, and study duration (for example 28 days). Injectables-style mcg charts misrepresent the compound class.
Systemic half-life is the wrong primary metric. Interest centers on local cutaneous activity and formula stability rather than plasma PK.
Yes in formulation research: it is often paired with Argireline-class peptides, hydrators, and delivery enhancers. Injectable stacking is not the evidence-based use case.
No. It is a topical cosmetic peptide investigated as a milder SNARE-pathway approach. It is not a botulinum toxin injection substitute in medical practice.
SNAP-8 is an elongated analogue of acetyl hexapeptide-8 (Argireline). Supplier comparisons claim incremental wrinkle-score improvements; independent effect sizes vary by vehicle and study quality.
Primary literature on SNAP-8. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides